Patents by Inventor Arnold Brossi

Arnold Brossi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THALIDOMIDE ANALOGS
    Publication number: 20140309436
    Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
  • Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
    Patent number: 8691864
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: April 8, 2014
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Thalidomide analogs
    Patent number: 8546430
    Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: October 1, 2013
    Assignee: P2D, Inc.
    Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
  • Thalidomide Analogs
    Publication number: 20130035363
    Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
    Type: Application
    Filed: October 10, 2012
    Publication date: February 7, 2013
    Applicants: The United States of America as represented by the Department of Health & Human Services, P2D INC.
    Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
  • Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
    Publication number: 20120295946
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: July 26, 2012
    Publication date: November 22, 2012
    Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
    Patent number: 8258172
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: September 4, 2012
    Assignees: Raptor Pharmaceutical Corp, National Institutes of Health (NIH)
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Tylophorine analogs as antitumor agents
    Patent number: 8188089
    Abstract: Compounds of Formula I are described: preferably subject to the proviso that either (a) R2 and R3 together form —O—CH(R10)—O—, or (b) R5 and R6 together form —O—CH(R10)—O—, wherein R10 is H, halo, or loweralkyl. Pharmaceutical salts, formulations, and methods of using the same in the treatment of cancer are also described.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: May 29, 2012
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Kuo-Hsiung Lee, Linyi Wei, Kenneth F. Bastow, Arnold Brossi, Tian-Shung Wu
  • THALIDOMIDE ANALOGS
    Publication number: 20110245210
    Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
    Type: Application
    Filed: June 3, 2011
    Publication date: October 6, 2011
    Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
  • Thalidomide analogs
    Patent number: 7973057
    Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
    Type: Grant
    Filed: September 17, 2004
    Date of Patent: July 5, 2011
    Assignees: The United States of America as represented by the Department of Health and Human Services, P2D Inc.
    Inventors: Nigel H. Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William D. Figg
  • Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
    Publication number: 20110021594
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: July 22, 2010
    Publication date: January 27, 2011
    Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof
    Patent number: 7786162
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: August 31, 2010
    Assignees: Raptor Pharmaceutical Corp., National Institutes of Health (NIH)
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane M. Davidson, Michael Sturgess
  • Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
    Publication number: 20090131501
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: January 21, 2009
    Publication date: May 21, 2009
    Applicants: TorreyPines Therapeutics, National Institutes of Health (NIH)
    Inventors: Nigel H. Greig, Karen T.Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Tada Utsuki, Timothy T. Soncrant, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Tylophorine Analogs as Antitumor Agents
    Publication number: 20080300254
    Abstract: Compounds of Formula I are described: preferably subject to the proviso that either (a) R2 and R3 together form —O—CH(R10)—O—, or (b) R5 and R6 together form —O—CH(R10)—O—, wherein R10 is H, halo, or loweralkyl. Pharmaceutical salts, formulations, and methods of using the same in the treatment of cancer are also described.
    Type: Application
    Filed: December 20, 2006
    Publication date: December 4, 2008
    Inventors: Kuo-Hsiung Lee, Linyi Wei, Kenneth F. Bastow, Arnold Brossi, Tian-Shung Wu
  • Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
    Patent number: 7153882
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: December 26, 2006
    Assignees: The United States of America as represented by the Department of Health and Human Services, The National Institutes of Health and Axonyx, Inc.
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Timothy T. Sencrant, Tada Utsuki, Donald Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Agents useful for reducing amylioid precursor protein and treating dementia and methods of use thereof
    Publication number: 20060270729
    Abstract: The present invention provides compounds and methods of administering compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce ?APP production and that is not toxic in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease ?APP production.
    Type: Application
    Filed: June 20, 2006
    Publication date: November 30, 2006
    Inventors: Nigel Greig, Karen Shaw, Qiang-Sheng Yu, Harold Holloway, Tada Utsuki, Timothy Soncrant, Donald Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Thalidomide analogs
    Publication number: 20060211728
    Abstract: Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-?) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.
    Type: Application
    Filed: September 17, 2004
    Publication date: September 21, 2006
    Inventors: Nigel Greig, Harold Holloway, Arnold Brossi, Xiaoxiang Zhu, Tony Giordano, Qian-sheng Yu, William Figg
  • Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
    Publication number: 20040138282
    Abstract: The present invention provides compounds and methods of administering compounds to a subject taht can reduce &bgr;APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce &bgr;APP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease &bgr;APP production.
    Type: Application
    Filed: February 6, 2004
    Publication date: July 15, 2004
    Inventors: Nigel H. Greig, Karen T. Y. Shaw, Qiang-Sheng Yu, Harold W. Holloway, Timothy T. Sencrant, Tada Utsuki, Donald K. Ingram, Arnold Brossi, Anthony Giordano, Gordon Powers, Diane Davidson, Michael Sturgess
  • Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias
    Patent number: 6683105
    Abstract: A method for treating cognitive impairments associated with aging or Alzheimer's disease which comprises treating a patient at risk for having the cognitive impairment with an effective amount of a highly selective butyrylcholinesterase inhibitor which is N8-benzylnorcymserine, N1-phenethylnorcymserine, N1, N8-bisnorcymserine, N1-N8-bisbenzylnorphysostigmine, N1, N8-bisbenzylnorphenserine, N1, N8-bisbenzylnorcymserine, or pharmaceutical acceptable salts thereof.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: January 27, 2004
    Assignee: Axonyx, Inc.
    Inventors: Nigel H. Greig, Qian-Sheng Yu, Arnold Brossi, Timothy T. Soncrant, Marvin Hausman
  • Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of Alzheimer's disease and dementias
    Publication number: 20020094999
    Abstract: The present disclosure relates to the discovery that highly selective butyrylcholinesterase inhibitors can prevent or treat cognitive impairments associated with aging or Alzheimer's disease. A preferred butyrylcholinesterase inhibitor is cymserine.
    Type: Application
    Filed: February 7, 2002
    Publication date: July 18, 2002
    Inventors: Nigel H. Greig, Qian-Sheng Yu, Arnold Brossi, Timothy T. Soncrant, Marvin Hausman
  • Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
    Patent number: 6410747
    Abstract: A method for preventing or treating cognitive impairments associated with aging or Alzheimer's disease which comprises treating a patient at risk for having the cognitive impairment with an effective amount of a highly selective butyrylcholinesterase inhibitor.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: June 25, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Nigel H. Greig, Qian-Sheng Yu, Arnold Brossi, Timothy T. Soncrant, Marvin Hausman